A Phase II, Multicenter, Randomized, Positive-Controlled, and Multi-Cohort Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites
Latest Information Update: 15 Jun 2023
Price :
$35 *
At a glance
- Drugs Recombinant human serum albumin (Primary) ; Albumin human
- Indications Ascites; Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Wuhan Healthgen Biotechnology
- 05 Apr 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Nov 2021).
- 12 Apr 2021 New trial record